Moderna Inc (NASDAQ:MRNA) price on Thursday, November 14, fall -5.62% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $39.77.
A look at the stock’s price movement, the close in the last trading session was $42.14, moving within a range at $38.76 and $42.05. The beta value (5-Year monthly) was 1.69. Turning to its 52-week performance, $170.47 and $41.54 were the 52-week high and 52-week low respectively. Overall, MRNA moved -30.79% over the past month.
Moderna Inc’s market cap currently stands at around $15.30 billion, with investors looking forward to this quarter’s earnings report slated for in December.
Analysts have a consensus estimate of 1.03B for the company’s revenue for the quarter, with a low and high estimate of 861.12M and 1.38B respectively. The average forecast suggests down to a -63.50% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 3.31B, representing a -51.69% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that MRNA is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
17 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 12 recommend MRNA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 2 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
MRNA’s current price about -21.88% and -32.92% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 14.66, while 7-day volatility ratio is 7.74% and 5.25% in the 30-day chart. Further, Moderna Inc (MRNA) has a beta value of 1.59, and an average true range (ATR) of 2.86. Analysts have given the company’s stock an average 52-week price target of $145, forecast between a low of $55 and high of $304. Looking at the price targets, the low is -38.3% off current price level while to achieve the yearly target high, price needs to move -664.4%. Nonetheless, investors will most likely welcome a -264.6% jump to $145 which is the analysts’ median price.
If we refocus on Moderna Inc (NASDAQ:MRNA), historical trading data shows that trading volumes averaged 9.59 over the past 10 days and 5.66 million over the past 3 months. The company’s latest data on shares outstanding shows there are 382.00 million shares.
The 10.83% of Moderna Inc’s shares are in the hands of company insiders while institutional holders own 66.72% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 34.38 million on 2024-10-31, giving us a short ratio of 7.59. The data shows that as of 2024-10-31 short interest in Moderna Inc (MRNA) stood at 1175.0 of shares outstanding, with shares short rising to 31.32 million registered in 2024-09-30. Current price change has pushed the stock -60.01% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the MRNA stock continues to rise going into the next quarter.
